Cecilia Radu – General Manager, Novo Nordisk Romania
Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market…
Address: Str. Academiei, Nr. 28 – 30, etaj 5, sector 1, Bucuresti, cod postal 010016, Romania
Tel: +4021.312.36.74
Web: http://www.novonordisk.ro/
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Diabetes care
Haemostasis management (NovoSeven® )
Growth hormone therapy
Hormone replacement therapy (HRT)
Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market…
You have become the head of Novo Nordisk’s operations in Romania in March 2008. Can you first give our readers an idea on how the market environment was at that…
Norina Alinta Gavan, CEO of Wörwag Pharma Romania, reveals how the affiliate will become more active and entrepreneurial with the change in shareholding while having an increased responsibility for the…
Simona Cocos of Zentiva Romania explains how the affiliate has developed since its separation from Sanofi and how recent acquisitions have impacted local operations. She shares how the extremely diversified…
Pascal Robin, country chair of Sanofi and general manager of Sanofi Pasteur for Romania and Moldova, shares his insights on the intrinsic and extrinsic factors that helped Sanofi become a…
Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a state-of-art stem cell therapy. She highlights the…
Iulia Arif-Percă executive director of the Local American Working Group (LAWG), shares her insights on the launched initiatives to finding new funding alternatives that will increase Romanian patients’ access to…
Dan Zaharescu, executive director of the Romanian Association of Pharmaceutical Manufacturers (ARPIM), shares his insights on market access, the need to reform pricing methodologies, the debate around the claw-back tax,…
László Attila, president of the Committee of Public Health of Romania, highlights the Committee’s efforts to mitigate the detrimental effects of Romania’s looming demographic crisis and medical “brain-drain”. Furthermore, he…
Valentina Băicuianu and Adrian Grecu of the APMGR, share their insights on the deteriorating environment for generics in Romania, with unfavourable pricing methodology and a rising and an unpredictable clawback…
Schalk Opperman, general manager of Merck Romania explains the key factors behind successful product launches in what is an unpredictable market. He shares his insights on Merck’s impressive growth in…
State hospitals in Bucharest are increasingly overloaded with patients due to a lack of resources and specialists. This pressure is amplified by the fact that many Romanians turn to emergency…
The Romanian Association of the Self-Care Industry (RASCI) was established in 2016 as the “voice” of the Romanian consumer healthcare industry. Diana Mereu, CEO of RASCI, discusses the association’s mission,…
As anti-vaccination sentiments resurface globally, so have once-eradicated diseases. This situation is especially prevalent in Romania and has become a severe economic, social, and health threat. Romania’s Struggle with…
See our Cookie Privacy Policy Here